Methylenedioxyallylamphetamine

For other uses, see MDAL (disambiguation).
MDAL
Clinical data
Other namesMDAL; 3,4-Methylenedioxy-N-allylamphetamine
Routes of
administration		Oral[1]
ATC code
  • None
Pharmacokinetic data
Duration of actionUnknown[1]
Identifiers
  • N-[1-(2H-1,3-benzodioxol-5-yl)propan-2-yl]prop-2-en-1-amine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC13H17NO2
Molar mass219.284 g·mol−1
3D model (JSmol)
  • C1=C2C(=CC=C1CC(C)NCC=C)OCO2
  • InChI=1S/C13H17NO2/c1-3-6-14-10(2)7-11-4-5-12-13(8-11)16-9-15-12/h3-5,8,10,14H,1,6-7,9H2,2H3 N
  • Key:BMKCDDFQEGYEJC-UHFFFAOYSA-N N
 NY (what is this?)  (verify)

Methylenedioxyallylamphetamine (MDAL or 3,4-methylenedioxy-N-allylamphetamine) is a lesser-known drug.[1] It is also the N-allyl derivative of 3,4-methylenedioxyamphetamine (MDA).[1] MDAL was first synthesized by Alexander Shulgin.[1] In his book PiHKAL, the minimum dose is listed as 180 mg, and the duration unknown.[1] MDAL produces few to no effects on its own, but may enhance the effects of psychedelic drugs like LSD.[1] Very little data exists about the pharmacological properties, metabolism, and toxicity of MDAL.[1]

Society and culture

United Kingdom

This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.[2]

See also

References

  1. ^ a b c d e f g h MDAL entry in PiHKAL
  2. ^ "UK Misuse of Drugs act 2001 Amendment summary". Isomer Design. Archived from the original on 22 October 2017. Retrieved 12 March 2014.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.